The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions - 10/08/11
, Jerry Tan, MD, FRCPC b, Yves Poulin, MD c, Thomas Dirschka, MD d, Nabil Kerrouche, MSc e, Vasant Manna, MD e
Reprint requests: Steven R. Feldman, MD, PhD, Department of Dermatology, School of Medicine, Wake Forest University, Medical Center Blvd, Winston-Salem, NC 27157.Abstract |
Background |
There is no direct correlation between acne severity and lesion numbers and patients with moderate acne may present with varying lesion counts. The fixed-dose adapalene 0.1%-benzoyl peroxide (BPO) 2.5% combination gel is an efficacious and safe acne treatment.
Objective |
We sought to evaluate whether the benefit of adapalene-BPO relative to vehicle varies with baseline lesion counts.
Methods |
Data were pooled from 3 randomized, double-blind, controlled studies, which compared efficacy in 4 treatment groups (adapalene-BPO, adapalene, BPO, and the gel vehicle). Three lesion count subgroups (Low, Mid, and High) were defined based on the number of total, inflammatory, or noninflammatory lesion at baseline. Efficacy of each treatment and benefit of each treatment relative to vehicle were evaluated on the entire population and in all lesion count subgroups. Safety was assessed by local tolerability score and adverse events.
Results |
Adapalene-BPO provided significant benefit relative to vehicle and monotherapies on the entire population and in all lesion count subgroups (P < .05). At study end point, the benefit of adapalene-BPO relative to vehicle was greatest in the High subgroup, suggesting that patients with the highest baseline lesion counts contributed the most to the treatment benefit observed in the entire population. This effect was only observed with adapalene-BPO and not with monotherapies. Higher baseline lesion counts did not lead to more related adverse event or worse tolerability score for adapalene-BPO.
Limitation |
These results were generated from clinical trials. Results in clinical practice could differ.
Conclusion |
The relative benefit of adapalene-BPO increases with higher lesion counts at baseline.
Le texte complet de cet article est disponible en PDF.Key words : acne, adapalene, benzoyl peroxide, combination therapy, lesion, severity
Plan
| Supported by Galderma Research and Development. |
|
| Disclosure: Dr Feldman received grant funding from and serves as speaker and consultant for Galderma. Dr Tan serves as speaker, investigator, and consultant for Galderma. Dr Poulin received grant funding from and serves as investigator for Galderma. Dr Dirschka received grant funding from and serves as advisor and speaker for Galderma. Mr Kerrouche and Dr Manna are employees of Galderma. |
Vol 64 - N° 6
P. 1085-1091 - juin 2011 Retour au numéro
Article précédent
- Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial
- Inge M. Haeck, Mirjam J. Knol, Onno ten Berge, Sara G.A. van Velsen, Marjolein S. de Bruin-Weller, Carla A.F.M. Bruijnzeel-Koomen
- Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: Reappraisal of epidemiological, clinical, and pathological features
- Antonio Martorell-Calatayud, Onofre Sanmartín, Rafael Botella-Estrada, Nicole N. Balmer, Carlos Serra-Guillén, Elisabeth Gomez-Moyano, Victor Traves-Zapata, Celia Requena, Eduardo Nagore, Beatriz Llombart-Cussac, Carlos Guillen-Barona
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?